ASCO 2023: Continued Success With Immunotherapy in Melanoma
At ASCO 2023, researchers reported positive results with nivolumab plus relatlimab, a cancer vaccine plus pembrolizumab, and pembrolizumab alone in patients with melanoma.
At ASCO 2023, researchers reported positive results with nivolumab plus relatlimab, a cancer vaccine plus pembrolizumab, and pembrolizumab alone in patients with melanoma.
At ASCO 2023, investigators reported results from phase 3 trials that could improve therapeutic approaches to bladder, prostate, and kidney cancer.
Studies presented at ASCO 2023 answered some questions about de-escalating treatment and how age impacts outcomes in patients with HER2-positive breast cancer.
Research presented at ASCO 2023 highlights the latest developments in gastrointestinal cancer treatment.
Studies presented at the ASCO Annual Meeting 2023 highlighted new developments in lymphoma that could lead to changes in practice.
Studies of CAR T-cell therapies presented at ASCO 2023 broke new ground and may change practice, according to researchers.
Sunvozertinib has demonstrated antitumor activity in patients with advanced NSCLC who have EGFR exon 20 insertions.
Studies from ASCO 2023 revealed new potential standards of care for multiple myeloma and a first for bispecific antibody therapy.
Adjuvant pembrolizumab provides a continued benefit for patients with stage IIB or IIC melanoma at 3 years, updated data suggest.
Gemcitabine plus cisplatin provides benefits over 5-fluorouracil plus cisplatin as adjuvant treatment for nasopharyngeal carcinoma, phase 3 data suggest.